RVM
XLO icon

RiverVest Venture Management’s Xilio Therapeutics XLO Stock Holding History

RiverVest Venture Management’s Portfolio XLO Stock Details XLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$1.14M Hold
102,960
– – 16.6% 3
2024
Q2 		$1.37M Hold
102,960
– – 20.01% 3
2024
Q1 		$1.56M Hold
102,960
– – 19.12% 3
2023
Q4 		$793K Hold
102,960
– – 2.92% 4
2023
Q3 		$3.04M Hold
102,960
– – 7.52% 4
2023
Q2 		$3.78M Hold
102,960
– – 4.19% 5
2023
Q1 		$4.57M Hold
102,960
– – 5.29% 5
2022
Q4 		$3.88M Hold
102,960
– – 4.52% 4
2022
Q3 		$4.2M Hold
102,960
– – 4.87% 4
2022
Q2 		$4.21M Hold
102,960
– – 6.19% 4
2022
Q1 		$10.2M Hold
102,960
– – 10.46% 3
2021
Q4 		$23.1M Buy
+102,960
New +$24.6M 16.45% 3

Other funds holding XLO

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $50.9B AUM 42.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return